Cargando…

Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Detalles Bibliográficos
Autores principales:	Hahn, Andreas, Günther, René, Ludolph, Albert, Schwartz, Oliver, Trollmann, Regina, Weydt, Patrick, Weiler, Markus, Neuland, Kathrin, Schwaderer, Martin Sebastian, Hagenacker, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597989/ https://www.ncbi.nlm.nih.gov/pubmed/36284315 http://dx.doi.org/10.1186/s13023-022-02548-7

Ejemplares similares

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
por: Sergott, Robert C., et al.
Publicado: (2020)

An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
por: Kwon, Jennifer M., et al.
Publicado: (2022)

Biomarkers in 5q-associated spinal muscular atrophy—a narrative review
por: Lapp, H. S., et al.
Publicado: (2023)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qiao, Yue, et al.
Publicado: (2023)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Disease burden of spinal muscular atrophy in Germany
por: Klug, Constanze, et al.
Publicado: (2016)

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
por: Binz, Camilla, et al.
Publicado: (2022)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

J wave syndromes in patients with spinal and bulbar muscular atrophy
por: Steinmetz, Karoline, et al.
Publicado: (2022)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Objective measurement of oral function in adults with spinal muscular atrophy
por: Kruse, T., et al.
Publicado: (2023)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters
por: Stolte, Benjamin, et al.
Publicado: (2021)

Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2021)

Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
por: Vill, Katharina, et al.
Publicado: (2021)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy
por: Schmitt, Linda-Isabell, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis
por: Wohnrade, Camilla, et al.
Publicado: (2023)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019)

Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment—A Pilot Study
por: Thimm, Andreas, et al.
Publicado: (2022)

Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients
por: Regensburger, Adrian P., et al.
Publicado: (2021)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Novel challenges in spinal muscular atrophy – How to screen and whom to treat?
por: Saffari, Afshin, et al.
Publicado: (2018)

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
por: Günther, René, et al.
Publicado: (2019)

Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy
por: Leo, Markus, et al.
Publicado: (2022)

High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy
por: Johannsen, Jessika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rvpd13a346ntkvd8210414bvdd